Effects of mirabegron on JJ stent-related symptoms: A multicentric study.

Abstract

To investigate the effect of mirabegron 50mg/daily for JJ stent-related symptoms after ureteroscopic stone surgery. Medical records of 145 patients who were given a single daily oral dose of 50mg of mirabegron for relieving stent-related symptoms were retrospectively analysed. Demographic and clinical data and stone parameters were recorded. All participants completed the Turkish version of the Ureter Symptom Score Questionnaire (USSQ-T) on the postoperative 7th day, and again after at least 3weeks, before JJ stent removal. The severity of stent-related symptoms was statistically compared before and after the mirabegron treatment. The mean urinary symptoms score decreased significantly from 30.87±9.43 to 22.61±6.78 (P<.0001), mean body pain score decreased significantly from 21.82±11.22 to 14.03±7.52 (P<.0001), mean work performance score decreased from 10.50±8.61 to 7.02±6.51 (P<.0001) and mean general health score decreased significantly from 15.43±6.50 to 11.12±3.70 (P<.0001). The mean sexual matters score significantly decreased from 3.88±3.40 to 2.48±2.03 (P<.0001), the additional problem score decreased from 9.31±4.61 to 6.51±2.83 (P<.0001) and the overall quality of life (QoL) score decreased from 5.18±1.94 to 4.23±1.71 after mirabegron use (P<.0001). Daily use of 50g of mirabegron significantly improved stent-related symptoms, sexual matters and quality of life.